ADC Therapeutics CEO Ameet Mallik (L) and CMO Mohamed Zaki

ADC Ther­a­peu­tics re­veals topline Zyn­lon­ta da­ta, $105M stock of­fer­ing

ADC Ther­a­peu­tics an­nounced a $105 mil­lion of­fer­ing af­ter shar­ing what it called pos­i­tive topline da­ta from a Phase 2 tri­al of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.